Article

Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 14, n° 5P1
pages 770-777 (mai 1986)
Doi : 10.1016/S0190-9622(86)70092-3
accepted : 16 January 1986
Large keratoacanthomas in difficult locations treated with intralesional 5-fiuorouracil
 

Colleen M. Parker, M.D. , C. William Hanke, M.D.
Department of Dermatology, Indiana University School of Medicine. 

aReprint requests to: Dr. Colleen M. Parker, Department of Dermatology, 1100 West Michigan St., Indianapolis, IN 46223.
@@#100979@@

Keratoacanthoma is a benign tumor; however, it may cause massive destruction of normal tissue during its rapid growth phase. Intralesional 5-fluorouracil (5-FU) has been shown to be an effective treatment for keratoacanthoma. We have successfully treated five patients with large keratoacanthomas in difficult locations. There have been no recurrences during follow-up periods ranging from 18 to 45 months. Intralesional 5-FU may be ineffective for keratoacanthomas that are not rapidly proliferating.

The full text of this article is available in PDF format.

Top of the page

© 1986  Published by Elsevier Masson SAS.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline
You can move this window by clicking on the headline
@@#110903@@